Myositis (IIM)

Categories: Bone diseases, Genetic diseases, Infectious diseases, Muscle diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Myositis

MalaCards integrated aliases for Myositis:

Name: Myositis 56 12 74 52 29 54 6 42 43 15 17 71 32
Idiopathic Inflammatory Myopathy 52 25 58
Idiopathic Inflammatory Myositis 52 25 58
Iim 56 52
Imm 52 58
Myopathy, Familial Idiopathic Inflammatory; Iim 56
Myopathy, Familial Idiopathic Inflammatory 56
Idiopathic Inflammatory Myopathy, Familial 52
Idiopathic Inflammatory Myopathies 25
Myopathies Idiopathic Inflammatory 54
Inflammatory Myopathy, Idiopathic 25
Inflammatory Disorder of Muscle 12



autosomal dominant


Inheritance autosomal dominant inheritance


Orphanet: 58  
Rare neurological diseases
Rare systemic and rhumatological diseases

External Ids:

Disease Ontology 12 DOID:633
OMIM 56 160750
MeSH 43 D009220
NCIt 49 C27578
SNOMED-CT 67 26889001
ICD10 32 M60 M60.9 M63.2
UMLS via Orphanet 72 C0751356
Orphanet 58 ORPHA98482
MedGen 41 C0027121
SNOMED-CT via HPO 68 128496001 249939004 263681008
UMLS 71 C0027121

Summaries for Myositis

Genetics Home Reference : 25 Idiopathic inflammatory myopathy is a group of disorders characterized by inflammation of the muscles used for movement (skeletal muscles). Idiopathic inflammatory myopathy usually appears in adults between ages 40 and 60 or in children between ages 5 and 15, though it can occur at any age. The primary symptom of idiopathic inflammatory myopathy is muscle weakness, which develops gradually over a period of weeks to months or even years. Other symptoms include joint pain and general tiredness (fatigue). There are several forms of idiopathic inflammatory myopathy, including polymyositis, dermatomyositis, and sporadic inclusion body myositis. Polymyositis and dermatomyositis involve weakness of the muscles closest to the center of the body (proximal muscles), such as the muscles of the hips and thighs, upper arms, and neck. People with these forms of idiopathic inflammatory myopathy may find it difficult to climb stairs, get up from a seated position, or lift items above their head. In some cases, muscle weakness may make swallowing or breathing difficult. Polymyositis and dermatomyositis have similar symptoms, but dermatomyositis is distinguished by a reddish or purplish rash on the eyelids, elbows, knees, or knuckles. Sometimes, abnormal calcium deposits form hard, painful bumps under the skin (calcinosis). In sporadic inclusion body myositis, the muscles most affected are those of the wrists and fingers and the front of the thigh. Affected individuals may frequently stumble while walking and find it difficult to grasp items. As in dermatomyositis and polymyositis, swallowing can be difficult.

MalaCards based summary : Myositis, also known as idiopathic inflammatory myopathy, is related to inclusion body myositis and granulomatous myositis, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Myositis is NARS1 (Asparaginyl-TRNA Synthetase 1), and among its related pathways/superpathways is tRNA Aminoacylation. The drugs Oseltamivir and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include lung, skeletal muscle and bone, and related phenotypes are myositis and proximal muscle weakness

Disease Ontology : 12 A myopathy characterized by muscle inflammation.

NIH Rare Diseases : 52 Idiopathic inflammatory myopathy refers to a group of conditions that affect the skeletal muscles (muscles used for movement). Although the condition can be diagnosed at any age, idiopathic inflammatory myopathy most commonly occurs in adults between ages 40 and 60 years or in children between ages 5 and 15 years. Signs and symptoms of the condition include muscle weakness, joint pain and fatigue. There are several forms of idiopathic inflammatory myopathy, including polymyositis , dermatomyositis , and sporadic inclusion body myositis , which are each associated with unique features. As the name suggests, the cause of the condition is currently unknown (idiopathic). However, researchers suspect that it may occur due to a combination of genetic and environmental factors . Treatment is supportive and based on the signs and symptoms present in each person.

MedlinePlus : 42 Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Other symptoms of myositis may include Fatigue after walking or standing Tripping or falling Trouble swallowing or breathing Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms. Polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. Other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 74 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

More information from OMIM: 160750

Related Diseases for Myositis

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 955)
# Related Disease Score Top Affiliating Genes
1 inclusion body myositis 35.0 SERPINA3 ICOSLG HLA-B DYSF APP
2 granulomatous myositis 34.4 TRIM21 PIK3C2A
3 dermatomyositis 33.8 TARS1 PIK3C2A IFIH1 GARS1
4 pyomyositis 33.8 PIK3C2A MB
5 antisynthetase syndrome 33.2 TARS1 HARS1
6 myopathy 32.6 TTN TRIM21 SERPINA3 PIK3C2A MB HLA-B
7 epidemic pleurodynia 32.6 PIK3C2A MB
8 exanthem 31.5 TRIM21 PIK3C2A IFIH1 ICOSLG
9 myocarditis 31.4 PIK3C2A MB HLA-B DMD
10 childhood type dermatomyositis 31.4 TRIM21 PIK3C2A IFIH1 ICOSLG HARS1
11 autoimmune disease 31.3 TRIM21 TGM2 PSMB9 ICOSLG HLA-B FBL
12 muscular dystrophy 31.3 TTN PIK3C2A MB DYSF DMD CAPN3
13 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 31.2 PIK3C2A MB
14 cellulitis 31.2 TGM2 SERPINA3 ICOSLG
15 giant cell myocarditis 31.1 MB HLA-B
16 gas gangrene 31.1 SERPINA3 PIK3C2A MB DMD
17 respiratory failure 30.9 TTN SERPINA3 PIK3C2A DMD
18 myoglobinuria 30.9 PIK3C2A MB DMD
19 limb-girdle muscular dystrophy 30.8 TTN DYSF DMD CAPN3
20 miyoshi muscular dystrophy 30.8 TTN PIK3C2A DYSF DMD CAPN3
21 spondyloarthropathy 1 30.7 PSMB9 ICOSLG HLA-B
22 muscular dystrophy, duchenne type 30.7 TTN PIK3C2A MB DMD
23 peripheral nervous system disease 30.7 SERPINA3 ICOSLG HARS1 GARS1 DMD APP
24 muscular dystrophy, becker type 30.7 PIK3C2A DYSF DMD CAPN3
25 neuromuscular disease 30.6 TTN SERPINA3 MB GARS1 DYSF DMD
26 progressive muscular dystrophy 30.5 MB DMD
27 myofibrillar myopathy 30.5 TTN SERPINA3 DYSF DMD CAPN3
28 localized lipodystrophy 30.3 DYSF DMD
29 muscular dystrophy-dystroglycanopathy , type c, 5 30.3 TTN DYSF CAPN3
30 dysferlinopathy 30.3 DYSF CAPN3
31 anterior compartment syndrome 30.2 MB DYSF
32 atrioventricular block 30.2 TTN TRIM21 PIK3C2A
33 panuveitis 30.2 SERPINA3 ICOSLG HLA-B
34 tibial muscular dystrophy 30.2 TTN DYSF DMD CAPN3
35 muscular dystrophy, limb-girdle, autosomal recessive 2 30.1 TTN DYSF DMD CAPN3
36 spinal muscular atrophy 30.1 GARS1 FBL DMD CAPN3 AARS1
37 myopathy, congenital 30.1 TTN DYSF DMD
38 muscular dystrophy, congenital, lmna-related 30.1 TTN DYSF DMD CAPN3
39 muscular disease 30.1 TTN SERPINA3 PIK3C2A MB IFIH1 ICOSLG
40 leiomyosarcoma 30.0 SERPINA3 PSMB9 MB
41 isolated elevated serum creatine phosphokinase levels 29.9 TTN PIK3C2A MB DYSF DMD CAPN3
42 congenital disorder of glycosylation, type iim 12.7
43 myositis ossificans 12.7
44 fibrodysplasia ossificans progressiva 12.6
45 myositis fibrosa 12.5
46 focal myositis 12.5
47 infective myositis 12.5
48 viral myositis 12.4
49 bacterial myositis 12.4
50 fungal myositis 12.4

Graphical network of the top 20 diseases related to Myositis:

Diseases related to Myositis

Symptoms & Phenotypes for Myositis

Human phenotypes related to Myositis:

# Description HPO Frequency HPO Source Accession
1 myositis 31 HP:0100614
2 proximal muscle weakness 31 HP:0003701

Symptoms via clinical synopsis from OMIM:

proximal muscle weakness

Clinical features from OMIM:


UMLS symptoms related to Myositis:

muscle weakness, myoclonus, myalgia, back pain, torticollis, sciatica, muscle cramp, muscle rigidity, muscle spasticity

GenomeRNAi Phenotypes related to Myositis according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.78 CAPN3 PIK3C2A
2 Decreased viability GR00055-A-2 9.78 CAPN3 PIK3C2A
3 Decreased viability GR00055-A-3 9.78 CAPN3 PIK3C2A
4 Decreased viability GR00221-A-1 9.78 PIK3C2A
5 Decreased viability GR00221-A-2 9.78 PIK3C2A TTN
6 Decreased viability GR00221-A-4 9.78 DYSF PIK3C2A TTN
7 Decreased viability GR00240-S-1 9.78 PIK3C2A TRIM21
8 Decreased viability GR00249-S 9.78 FBL HLA-B PIK3C2A SERPINA3
9 Decreased viability GR00301-A 9.78 DYSF
10 Decreased viability GR00342-S-1 9.78 PIK3C2A TTN
11 Decreased viability GR00342-S-2 9.78 PIK3C2A
12 Decreased viability GR00342-S-3 9.78 PIK3C2A TTN
13 Decreased viability GR00386-A-1 9.78 ICOSLG MB
14 Decreased viability GR00402-S-2 9.78 DMD GARS1 TARS1
15 Decreased hepcidin::fluc mRNA expression GR00253-A 9.26 AARS1 DMD GARS1 NARS1

MGI Mouse Phenotypes related to Myositis:

# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.28 AARS1 APP CAPN3 DMD DYSF GARS1

Drugs & Therapeutics for Myositis

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
Simvastatin Approved Phase 4 79902-63-9 54454
Ezetimibe Approved Phase 4 163222-33-1 150311
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Atorvastatin Approved Phase 4 134523-00-5 60823
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
12 Anti-Infective Agents Phase 4
13 Anti-HIV Agents Phase 4
14 Antiviral Agents Phase 4
15 Anti-Retroviral Agents Phase 4
16 Reverse Transcriptase Inhibitors Phase 4
17 Protective Agents Phase 4
18 Antioxidants Phase 4
19 Trace Elements Phase 4
20 Vitamins Phase 4
21 Nutrients Phase 4
22 Micronutrients Phase 4
23 Vitamin B Complex Phase 4
24 Folate Phase 4
25 Vitamin B9 Phase 4
26 Ezetimibe, Simvastatin Drug Combination Phase 4
27 Liver Extracts Phase 4
28 Vasodilator Agents Phase 4
29 Nicotinic Acids Phase 4
30 Vitamin B3 Phase 4
31 Hypolipidemic Agents Phase 4
32 Lipid Regulating Agents Phase 4
33 Antimetabolites Phase 4
34 Anticholesteremic Agents Phase 4
35 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
Infliximab Approved Phase 2, Phase 3 170277-31-3
leucovorin Approved Phase 3 58-05-9 6006 143
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
Lenograstim Approved, Investigational Phase 3 135968-09-1
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
Abatacept Approved Phase 3 332348-12-6 10237
belimumab Approved Phase 2, Phase 3 356547-88-1 10451420 5957
Sodium citrate Approved, Investigational Phase 3 68-04-2
Denosumab Approved Phase 3 615258-40-7
Risedronate Approved, Investigational Phase 3 105462-24-6 5245

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
3 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
4 Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
5 Rho-kinase in Patients With Atherosclerosis: Effects of Statins A Randomized Clinical Trial Comparing Ezetimibe/Simvastatin and Simvastatin Completed NCT00560170 Phase 4 Simvastatin (Zocor);10mg/10mg of Ezetimibe/Simvastatin (Vytorin)
6 The Effects of Melatonin on Elevated Liver Enzymes During Statins Treatment Completed NCT03121521 Phase 4 Melatonin 10 mg;Placebo
7 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
8 Double Blind, Prospective Randomized, Crossover Study of Patients With Muscle Complaints on Statin Therapy Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
9 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
10 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
11 Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
12 Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI" Completed NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
13 An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies Completed NCT00443222 Phase 2, Phase 3 Infliximab
14 An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
15 Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02573467 Phase 3 Bimagrumab;Placebo
16 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
17 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
18 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
19 Effect of 80-mg Atorvastatin on Myocardial Edema Following Coronary Artery Bypass Surgery in Relation With Follistatin-Like Protein-1 Completed NCT02901379 Phase 3 Atorvastatin 80mg;Atorvastatin 10mg
20 High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma) Completed NCT00501995 Phase 3 IV Cyclophosphamide
21 A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
22 High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage: Is it Better? Completed NCT01077206 Phase 2, Phase 3 Simvastatin
23 Evaluation of Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis Recruiting NCT03912428 Phase 3 Celecoxib
24 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Active, not recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
25 Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis Active, not recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
26 A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT03312634 Phase 3 Palovarotene
27 A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease Active, not recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
28 An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial Enrolling by invitation NCT04049097 Phase 3 Arimoclomol
29 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Not yet recruiting NCT04034199 Phase 3 Denosumab;Zoledronic Acid
30 Intraorbital Injection Versus Oral Steroid in Patients With Anterior Idiopathic Orbital Inflammation: A Randomized Clinical Trial Not yet recruiting NCT03958344 Phase 3 Prednisolone;Triamcinolone + Betamethason
31 Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial Not yet recruiting NCT03770663 Phase 3 Cyclophosphamide and azathioprine;Tacrolimus
32 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
33 A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
34 A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
35 Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
36 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed NCT02043548 Phase 2 tocilizumab;placebo
37 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
38 FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
39 Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors. Completed NCT00519363 Phase 1, Phase 2 atorvastatin
40 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Completed NCT02190747 Phase 2 Palovarotene;Placebo
41 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
42 A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Coadministered With Fenofibrate in Subjects With Combined Hyperlipidemia Completed NCT00813527 Phase 2 Lapaquistat acetate and fenofibrate;Fenofibrate
43 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
44 Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
45 A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
46 A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients Completed NCT00005571 Phase 2 h5G1.1-mAb
47 Phase II Clinical Trial to Examine the Efficacy and Safety of Dutasteride in Patients With Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) Completed NCT00303446 Phase 2 Dutasteride;Placebo
48 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
49 A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Recruiting NCT04033926 Phase 2 KZR-616;Placebo
50 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

chlorphenesin carbamate
Cyclobenzaprine hydrochloride
Orphenadrine Citrate
Orphenadrine Hydrochloride
tizanidine hydrochloride

Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

Genetic tests related to Myositis:

# Genetic test Affiliating Genes
1 Myositis 29

Anatomical Context for Myositis

MalaCards organs/tissues related to Myositis:

Lung, Skeletal Muscle, Bone, T Cells, Skin, Testes, Heart

Publications for Myositis

Articles related to Myositis:

(show top 50) (show all 9371)
# Title Authors PMID Year
Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. 56 61
9550481 1998
32141855 2020
Fibrodysplasia ossificans progressiva-a rare disease with distinctive features yet still a diagnostic challenge: A case report. 42
32332674 2020
A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. 42
32282733 2020
Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers--possibly caused by endoplasmic reticulum stress. 61 54
20236612 2010
Gemfibrozil-induced myositis in a patient with normal renal function. 54 61
19934390 2010
Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. 54 61
19833747 2009
Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. 61 54
19644880 2009
Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. 54 61
18628284 2009
Eosinophilic myositis in calpainopathy: could immunosuppression of the eosinophilic myositis alter the early natural course of the dystrophic disease? 61 54
19285864 2009
[Hypothyroidism with leading myopathy in a patient suffering from systemic lupus erythematosus and Hashimoto's thyroiditis]. 54 61
18936898 2008
Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. 61 54
18974565 2008
Distal inflammatory myopathy: unusual presentation of polymyositis or new entity? 61 54
18534849 2008
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. 54 61
18420712 2008
Adults with eosinophilic myositis and calpain-3 mutations. 61 54
18299526 2008
Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic deletion and evidence for messenger RNA decay. 61 54
17979987 2007
NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in A beta PP-overexpressing cultured human muscle fibers. 61 54
17764014 2007
Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. 54 61
17277004 2007
[Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report]. 54 61
18320790 2007
Rituximab for refractory polymyositis: an open-label prospective study. 54 61
17722224 2007
Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. 61 54
17763431 2007
Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. 54 61
17665459 2007
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. 54 61
17606177 2007
Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. 54 61
17616993 2007
Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. 61 54
17405833 2007
Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. 54 61
17420473 2007
Myostatin precursor protein is increased and associates with amyloid-beta precursor protein in inclusion-body myositis culture model. 54 61
17359364 2007
Expression of major histocompatibility complex class I and class II antigens in canine masticatory muscle myositis. 61 54
17360184 2007
Genetic determinants of statin intolerance. 54 61
17376224 2007
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. 61 54
17265504 2007
MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. 61 54
17077152 2006
Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. 61 54
16856153 2006
HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. 54 61
17057271 2006
Presymptomatic neuromuscular disorders disclosed following statin treatment. 61 54
16864763 2006
CAPN3 mutations in patients with idiopathic eosinophilic myositis. 61 54
16607617 2006
Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers. 61 54
17039976 2006
Neurological manifestations of dengue virus infection. 54 61
16524594 2006
Serum creatine kinase levels and renal function measures in exertional muscle damage. 61 54
16679975 2006
Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. 61 54
16431335 2006
Antisynthetase syndrome associated with sarcoidosis. 61 54
17043379 2006
Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. 54 61
16224247 2005
Role of major histocompatibility complex class I molecules in autoimmune myositis. 61 54
16224250 2005
Mdm muscular dystrophy: interactions with calpain 3 and a novel functional role for titin's N2A domain. 61 54
16115818 2005
Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. 54 61
16102434 2005
Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. 54 61
15983828 2005
Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. 54 61
16052580 2005
Benign acute childhood myositis. 61 54
15973022 2005
Beta-chemokine receptor expression in idiopathic inflammatory myopathies. 61 54
15772970 2005
Changes of single fiber electromyography in patients with inflammatory myopathies. 54 61
15844301 2005
Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. 61 54
15634233 2005

Variations for Myositis

ClinVar genetic disease variations for Myositis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FAM111B NM_198947.4(FAM111B):c.1462del (p.Cys488fs)deletion Likely pathogenic 599012 rs1565191262 11:58893032-58893032 11:59125559-59125559

Expression for Myositis

Search GEO for disease gene expression data for Myositis.

Pathways for Myositis

Pathways related to Myositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways

GO Terms for Myositis

Cellular components related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10 TTN TRIM21 TGM2 TARS1 PSMB9 PIK3C2A
2 cytosol GO:0005829 9.83 TTN TRIM21 TGM2 TARS1 PSMB9 PIK3C2A
3 extracellular exosome GO:0070062 9.5 TTN TGM2 TARS1 SERPINA3 PSMB9 PIK3C2A
4 astrocyte projection GO:0097449 9.26 DMD APP

Biological processes related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 translation GO:0006412 9.35 TARS1 NARS1 HARS1 GARS1 AARS1
2 muscle fiber development GO:0048747 9.26 DYSF DMD
3 tRNA aminoacylation GO:0043039 9.16 TARS1 AARS1
4 tRNA aminoacylation for protein translation GO:0006418 9.02 TARS1 NARS1 HARS1 GARS1 AARS1

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.97 TTN TARS1 PIK3C2A NARS1 IFIH1 HARS1
2 ATP binding GO:0005524 9.92 TTN TARS1 PIK3C2A NARS1 IFIH1 HARS1
3 identical protein binding GO:0042802 9.81 TTN TRIM21 TGM2 TARS1 IFIH1 ICOSLG
4 structural constituent of muscle GO:0008307 9.43 TTN DMD CAPN3
5 ligase activity GO:0016874 9.35 TARS1 NARS1 HARS1 GARS1 AARS1
6 aminoacyl-tRNA ligase activity GO:0004812 9.02 TARS1 NARS1 HARS1 GARS1 AARS1

Sources for Myositis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....